Friday, 20 July 2018 - 7:58
  • it
  • de
  • en
  • fr

Galapagos NV

Gilead-Galapagos’ Filgotinib shows efficacy in treating psoriatic arthritis

Gilead Sciences and Belgium-based biotech Galapagos yesterday announced, after Wall Street closed, data from the Phase II EQUATOR trial assessing filgotinib on 131 patients with psoriatic arthritis. The results are positive and demonstrate that filgotinib improves patients’ conditions after as…

Galapagos tries to avoid being acquired by Gilead

The Dutch economic and financial daily Het Financieele Dagblad has published today a front-page article reporting that Belgium-based biotech Galapagos is looking for an important shareholder protecting it from Gilead. Gilead already owns 13% of the company. Galapagos CEO Van…

Gilead closer and closer to acquiring Galapagos (€3.96bn)

Rumors about Gilead actually targeting Belgian biotech company Galapagos are starting circulating again. The news has been reported by Belgian economic-financial daily De Tijd, which has mentioned a statement by Galapagos’ CEO Onno Van de Stolpe. The two companies in…